Depatux-M对EGFR扩增复发胶质母细胞瘤患者健康相关生活质量与神经功能的影响:EORTC 1410/INTELLANCE 2 II期试验
该研究为EORTC 1410/INTELLANCE 2随机II期试验的预设探索性分析,纳入260例EGFR扩增复发胶质母细胞瘤患者,比较Depatux-M联合替莫唑胺、Depatux-M单药与替莫唑胺/洛莫司汀的HRQoL和神经功能恶化自由生存(NDFS)。结果显示除视觉障碍在Depatux-M组临床相关恶化外,HRQoL和NDFS在各治疗组间总体相似。
要点
- Depatux-M组视觉障碍较TMZ/CCNU组在所有时间点出现临床相关恶化(平均差异24.6-35.1分)。
- 整体健康/生活质量状态在各治疗组间差异未达临床相关性(≥10分)。
- NDFS及其他HRQoL量表变化在各治疗组间总体相似。
核心结论
- Depatux-M对EGFR扩增复发胶质母细胞瘤患者的HRQoL和NDFS无显著影响,但视觉障碍更多,为该药预期副作用。
研究设计与样本
- EORTC 1410/INTELLANCE 2随机II期试验的预设HRQoL和NDFS探索性分析,共纳入260例EGFR扩增复发胶质母细胞瘤患者。
- 患者按1:1:1随机接受Depatux-M 1.25 mg/kg或1.0 mg/kg每2周静脉联合口服替莫唑胺150 mg/m2、Depatux-M单药、或替莫唑胺/口服洛莫司汀110 mg/m2。
- 使用EORTC QLQ-C30和QLQ-BN20问卷在基线、第8周、第16周和第6个月评估HRQoL,并计算从基线至各时间点的变化。
- NDFS定义为至世界卫生组织体力状况首次恶化的时间。
主要发现
- HRQoL问卷依从率基线为88.1%,第6个月降至37.9%。
- Depatux-M组与TMZ/CCNU组在治疗期间整体健康/生活质量状态较基线的差异未达临床相关性(≥10分)。
- Depatux-M组自报视觉障碍较TMZ/CCNU组在所有时间点出现临床相关恶化(平均差异范围24.6-35.1分)。
- 其他HRQoL量表从基线的变化和NDFS在各治疗组间总体相似。
临床怎么用
- 在EGFR扩增复发胶质母细胞瘤中使用Depatux-M时,应关注视觉障碍这一预期副作用,并常规评估HRQoL和神经功能状态。
局限性
- HRQoL问卷依从率从基线88.1%下降至第6个月37.9%,可能影响长期生活质量数据的解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the EORTC 1410/INTELLANCE 2 randomised, phase II study (NCT02343406), with the antibody-drug conjugate depatuxizumab mafodotin (Depatux-M, ABT-414) in patients with recurrent EGFR-amplified glioblastoma, the primary end-point (overall survival) was not met, and the drug had ocular dose-limiting toxicity. This study reports results from the prespecified health-related quality of life (HRQoL) and neurological deterioration-free survival (NDFS) exploratory analysis. PATIENTS AND METHODS: Patients (n = 260) were randomised 1:1:1 to receive either Depatux-M 1.25 mg/kg or 1.0 mg/kg intravenously every 2 weeks with oral temozolomide (TMZ) 150 mg/m2, Depatux-M alone, or TMZ or oral lomustine (CCNU) 110 mg/m2 (TMZ/CCNU). HRQoL outcomes were recorded using the EORTC core Quality of Life QLQ-C30, and brain cancer-specific QLQ-BN20 questionnaires. Questionnaires were completed at baseline, weeks 8 and 16, and month 6, and changes from baseline to each time point were calculated. NDFS was defined as time to first deterioration in World Health Organisation performance status. RESULTS: Compliance with HRQoL was 88.1% at baseline and decreased to 37.9% at month 6. Differences from baseline between Depatux-M arms and TMZ/CCNU in global health/QoL status throughout treatment did not reach clinical relevance (≥10 points). Self-reported visual disorders deteriorated to a clinically relevant extent with Depatux-M arms versus TMZ/CCNU at all timepoints (mean differences range: 24.6-35.1 points). Changes from baseline for other HRQoL scales and NDFS were generally similar between treatment arms. CONCLUSIONS: Depatux-M had no impact on HRQoL and NDFS in patients with EGFR-amplified recurrent glioblastoma, except for more visual disorders, an expected side-effect of the study drug. CLINICAL TRIAL REGISTRATION: NCT02343406.
引用
- Clement PMJ, Dirven L, Eoli M, et al. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. Eur J Cancer. 2021. PMID: 33601293. doi:10.1016/j.ejca.2021.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。